Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

被引：10
|
作者：
Bhojwani, Deepa
Sposto, Richard
Shah, Nirali
Rodriguez, Vilmarie
O'Brien, Maureen Megan
McNeer, Jennifer Lynn
Loh, Mignon L.
Rheingold, Susan R.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.10512
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10512
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Inotuzumab Ozogamicin (Besponsa®) for Patients with relapsed or refractory acute lymphoblastic Leukemia (r/r ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 66 - 66
  • [2] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    LEUKEMIA, 2019, 33 (04) : 884 - 892
  • [3] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [4] Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 1061 - 1062
  • [5] Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin
    Chahoud, Jad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Kadia, Tapan
    Cortes, Jorge E.
    Khouri, Maria R.
    Ravandi, Farhad
    Dahl, Jenny
    Ferrajoli, Alessandra
    Jacob, Jovitta
    Pemmaraju, Naveen
    Daver, Naval
    Garris, Rebecca
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [6] Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison
    Faderl, Stefan
    Jain, Nitin
    O'Brien, Susan Mary
    Thomas, Deborah A.
    Ravandi, Farhad
    Jabbour, Elias
    Pierce, Sherry
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome-positive (Ph plus ) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
    Stock, Wendy
    Martinelli, Giovanni
    Stelljes, Matthias
    DeAngelo, Daniel J.
    Gokbuget, Nicola
    Advani, Anjali S.
    O'Brien, Susan Mary
    Liedtke, Michaela
    Merchant, Akil Abid
    Cassaday, Ryan Daniel
    Wang, Tao
    Vandendries, Erik
    Marks, David I.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Sasaki, Koji
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Jain, Nitin
    Konopleva, Marina
    Estrov, Zeev
    Takahashi, Koichi
    Khouri, Maria R.
    Jacob, Jovitta
    Garris, Rebecca
    Cortes, Jorge E.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [9] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [10] Quality-adjusted life years (QALY) for inotuzumab ozogamicin vs standard of care for relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
    Van Oostrum, Ilse
    Su, Yun
    Heeg, Bart
    Wilke, Thomas
    Smith, Alexander
    Loberiza, Fausto Rodriguez
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345